EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
2020/06/01 by Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer +37 · 32 citations
Medicine · Immunology and Microbiology · #Spondyloarthritis Studies and Treatments #Rheumatoid Arthritis Research and Therapies #Psoriasis: Treatment and Pathogenesis
paper · pdf · doi:10.1136/annrheumdis-2020-217159
Abstract
OBJECTIVE: To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA). METHODS: According to the EULAR standardised operating procedures, a systematic literature review was followed by a consensus meeting to develop this update involving 28 international taskforce members in May 2019. Levels of evidence and strengths of recommendations were determined. RESULTS: The updated recommendations comprise 6 overarching principles and 12 recommendations. The overarching principles address the nature of PsA and diversity of both musculoskeletal and non-musculoskeletal manifestations; the need for collaborative management and shared decision-making is highlighted. The recommendations provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs and local glucocorticoid injections are proposed as initial therapy; for patients with arthritis and poor prognostic factors, such as polyarthritis or monoarthritis/oligoarthritis accompanied by factors such as dactylitis or joint damage, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drugs (bDMARDs) targeting tumour necrosis factor (TNF), interleukin (IL)-17A or IL-12/23 should be initiated, taking into account skin involvement if relevant. If axial disease predominates, a TNF inhibitor or IL-17A inhibitor should be started as first-line disease-modifying antirheumatic drug. Use of Janus kinase inhibitors is addressed primarily after bDMARD failure. Phosphodiesterase-4 inhibition is proposed for patients in whom these other drugs are inappropriate, generally in the context of mild disease. Drug switches and tapering in sustained remission are addressed. CONCLUSION: These recommendations provide stakeholders with an updated consensus on the pharmacological management of PsA, based on a combination of evidence and expert opinion.
Citations
Cited by
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
- 2026 EULAR updated standardised operating procedures and methods for the development of recommendations or points to consider for the diagnosis and management of people with rheumatic and musculoskeletal diseases
- Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial
- Physical fitness and physical activity in psoriatic arthritis: a systematic review
- Arthritis Mutilans in Psoriatic Arthritis: The Consequences of Delayed Treatment
- Predicting Treatment Outcomes in Patients With Psoriatic Arthritis or Axial Spondyloarthritis: An Artificial Intelligence–Driven Approach
- Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls
- Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. [europepmc]
- Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. [europepmc]
- The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. [europepmc]
- Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. [europepmc]
- Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. [europepmc]
- Treatment persistence of biologics among patients with psoriatic arthritis. [europepmc]
- Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. [europepmc]
- Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. [europepmc]
- Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. [europepmc]
- Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study. [europepmc]
- Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. [europepmc]
- A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. [europepmc]
- Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. [europepmc]
- Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). [europepmc]
- Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. [europepmc]
- Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database. [europepmc]
- Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. [europepmc]
- Psoriatic Arthritis: Pathogenesis and Targeted Therapies. [europepmc]
- EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders. [europepmc]
- IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. [europepmc]
- Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. [europepmc]
- Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment. [europepmc]
- Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. [europepmc]
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. [europepmc]
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. [europepmc]
Related